BEBT-209 capsules

DRUG4 trials

Sponsors

BeBetter Med Inc

Conditions

Advanced Breast CancerAdvanced Triple-Negative Breast CancerHR+/HER2- Locally Advanced, Metastatic Breast CancerLocally Advanced Triple-negative Breast CancerMetastatic Triple-negative Breast Cancer

Phase 1

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

BeBetter Med IncAdvanced Breast Cancer

Start: 2019-07-15End: 2023-11-20Target: 106Updated: 2023-09-21

Phase 2

A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

RecruitingNCT06685796

BeBetter Med IncAdvanced Triple-Negative Breast Cancer

Start: 2023-04-12End: 2026-12-31Target: 120Updated: 2024-11-13

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Not yet recruitingNCT07544056

BeBetter Med IncLocally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer

Start: 2026-04-01End: 2030-12-01Target: 446Updated: 2026-04-22

Phase 3

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

RecruitingNCT06998108

BeBetter Med IncHR+/HER2- Locally Advanced, Metastatic Breast Cancer

Start: 2022-06-09End: 2026-06-30Target: 330Updated: 2025-05-31

Related Papers

Efficacy and safety of BEBT-209, a primary CDK4 inhibitor, in combination with gemcitabine and carboplatin for metastatic triple-negative breast cancer.

Journal of Clinical Oncology2025-05-28